The researcher whose work led to migraine medicines used by millions will guide BetterLife’s headache program.

BetterLife Pharma (CSE: BETR) closed a US$100M offering, issuing 447M common shares at CDN$0.25 each and 108M pre-funded warrants. Proceeds will fund BETR-001 clinical trials for neurological disorders. Investors include Deep Track Capital and other healthcare-focused funds. The company granted agents a 7% commission and warrants.

BetterLife Pharma Inc. (CSE: BETR) filed a final prospectus for a US$100 million public offering of common shares and pre-funded warrants. The offering, led by Bloom Burton Securities and Haywood Securities, aims to raise up to US$100 million with a minimum of US$80 million. Proceeds will fund clinical trials for neurological disorder treatments and general corporate purposes. The offering is expected to close on or around September 17, 2026, subject to regulatory approvals.

Helen Chiang, who had been Xbox COO for 3 months, left Microsoft. CEO Asha Sharma confirmed her departure in an internal memo. Chiang had worked at Microsoft for 21 years. Xbox vice president of communications Kari Perez declined to comment further. This follows another recent departure of Jared Palmer, who left after 2 months as VP of Xbox Engineering.

Xencor (XNCR) announced positive early-stage trial results for its kidney cancer drug XmAb819, with tumor shrinkage in 48% of patients at the highest dose. The company plans to pursue accelerated approval and initiate a late-stage trial.

Genmab and Incyte will collaborate on a clinical trial to test their experimental cancer drugs with chemotherapy for advanced colorectal cancer patients with a specific genetic mutation, according to the companies.

AstraZeneca's Imfinzi showed benefits in bladder cancer patients in the VOLGA trial, presented at ESMO 2023. The drug, combined with Padcev, outperformed standard care in cisplatin-ineligible MIBC patients. The company is reviewing the data.